Moderna, the pharmaceutical giant, has recently introduced new mRNA vaccines aimed at treating the deadly side effects caused by COVID shots. During its Vaccines Day Event for investors on March 28, Moderna announced progress on multiple mRNA-based vaccines and therapeutic candidates in its “pipeline.”
The company revealed that it is advancing three vaccines targeting Epstein-Barr virus (EBV), Varicella-zoster virus (VZV), and Norovirus to pivotal late-stage development. Additionally, Moderna stated that the U.S. Food and Drug Administration (FDA) is expected to approve its respiratory syncytial virus (RSV) vaccine mRNA-1345 for older adults. This move is part of Moderna's plan to tap into the $52 billion market for infectious disease vaccines.
Furthermore, Moderna is exploring the application of mRNA in treating cardiovascular and other ischemic vascular diseases. The company is also developing mRNA solutions for cancer and autoimmune diseases.
However, some scientists and doctors have expressed concerns about the dangers of existing and new mRNA formulations, citing the well-documented and often serious adverse reactions to COVID-19 mRNA vaccines. They question whether Moderna is attempting to profit from solutions for diseases its products are causing.
Suppressing Innate Immunity
According to Brian Hooker, Ph.D., chief scientific officer at Children's Health Defense, synthetic-modified RNA (modRNA) used in mRNA vaccines suppresses innate immunity, which protects against new infections and keeps latent viruses at bay. One mechanism involves microRNAs that suppress the production of cellular interferon, an essential component in fighting viral infections and tumor suppression.
Studies have suggested that vaccine-induced interferon suppression blocks the proper functioning of CD8+ T cells, often referred to as the foot soldiers of the immune system. This can allow dormant viruses like Varicella-zoster virus (VZV) to reactivate and cause shingles, the adult version of chickenpox. Several cases of herpes zoster (shingles) reactivation following COVID-19 vaccination have been reported.
French scientist Hélène Banoun, Ph.D., has highlighted the disorganization of the innate immune system and its receptors as contributing factors to the reactivation of latent viruses. These include herpes, shingles, human papillomavirus (HPV), and respiratory syncytial virus (RSV).
Elevated IgG4 Antibodies and Autoimmune Diseases
Researchers have also raised concerns about the role of anti-spike IgG4 antibodies in spike-induced immunotolerance. These antibodies can prevent the immune system's T cells from attacking and killing cancer cells but can also bind to the same targets as other antibodies, blocking their effectiveness.
Overexpression of IgG4 can lead to IgG4-related disease, a chronic inflammatory condition that can dysregulate organ functioning and even cause death. A study showed that repeated vaccination with mRNA vaccines may generate immune tolerance to the SARS-CoV-2 spike protein, rendering the vaccines ineffective.
Abnormal IgG4 antibodies have been observed in nearly all mRNA-vaccinated individuals, raising concerns about their potential to trigger autoimmune diseases, cancer, and other illnesses. Some scientists believe that the induction of immunological tolerance by repeated vaccinations could explain the large number of deaths occurring in vaccinated individuals who received a third dose compared to unvaccinated individuals.
Turbo Cancers and Other Diseases
Geert Vanden Bossche, Ph.D., has warned that vaccine-induced elevated levels of IgG4 could lead to turbo cancers. Many oncologists have reported rapidly developing cancers, often in younger people, that have already progressed to Stage 3 or 4 by the time they are diagnosed.
Moderna is developing mRNA vaccines for various cancers, including melanoma, non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, and lymphomas. However, critics argue that these therapies may have unintended consequences and could induce immunotolerance to other diseases such as infections and cancers.
The Role of Spike Protein and Long COVID
There is growing evidence suggesting that the spike protein in the SARS-CoV-2 virus itself can cause many of the same diseases attributed to long COVID. Researchers have found elevated levels of antibodies related to Epstein-Barr virus, herpes virus 6A, and human endogenous retrovirus K in COVID-19-infected individuals.
Long COVID symptoms, which may overlap with those caused by mRNA vaccines, include difficulty breathing, chest pain, heart palpitations, fatigue, brain fog, sleep problems, and changes in taste or smell. These symptoms resemble those reported by people with chronic fatigue syndrome.
Jennifer Margulis discussed the chickenpox vaccine and its connection to the rise in shingles cases. She pointed out that the wild virus's removal through vaccination campaigns has reduced natural immunity in adults, leading to an increase in shingles cases. Moderna is developing mRNA-1468 as a vaccine to protect adults from shingles.
Moderna's Pipeline and Stock Performance
Apart from the vaccines mentioned above, Moderna has a wide range of products in its pipeline. These include an HIV vaccine, RSV-HPV vaccine, pandemic flu shot, cytomegalovirus vaccine, Lyme disease vaccine, Zika vaccine, Nipah vaccine, Mpox vaccine, and more. Moderna's stock value has risen by 11.2% in 2024, approaching $111 per share.
Conclusion
Moderna's unveiling of new mRNA vaccines to treat the side effects of COVID shots has sparked both excitement and concerns. While the company aims to address infectious diseases and various medical conditions, scientists and doctors have raised questions about the safety and potential risks associated with mRNA formulations.
The suppression of innate immunity, the elevation of IgG4 antibodies, and the spike protein's role in causing diseases have all been subjects of scrutiny. Critics argue that mRNA vaccines may contribute to the reactivation of latent viruses, the development of autoimmune diseases, and the progression of turbo cancers.
